Tag Archives: BIO Investor Forum

PTC Therapeutics Announces Phase III Trial of Ataluren

PTC Therapeutics, Inc. (PTC) initiated a Phase III trial of ataluren, an investigational protein restoration therapy for patients with nonsense mutation cystic fibrosis (nmCF). Ataluren is the first investigational drug designed to address the underlying cause of nonsense mutation cystic fibrosis. The primary objective of the registration-directed double-blind, placebo-controlled study is to evaluate whether ataluren can improve lung function, as measured by forced expiratory volume in one second (FEV1), in patients with nmCF. An orally Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

The latest from Trubion Pharmaceuticals

An interview with Dr. Peter A. Thompson, MD, FACP, President, CEO, & Chairman of the Board of Directors of Trubion Pharmaceuticals: What is one aspect of your company that you feel would be most attractive or exciting to investors? We currently have three product candidates in the clinic with two, strategic collaborations underlying their development – Wyeth for our CD20 programs and Facet for our CD37 programs. Data disclosures later this year from key clinical trials Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Forbes on Flu

Forbes’ Jonathan Fahey wrote an excellent article on influenza and the H1N1 virus this morning. The article is significant for a couple reasons. First, he captures the overall situation so just in case you haven’t read a story or heard about H1N1 yet (and have been living under a rock), you get the full picture quickly and succinctly. Even if you have read about it, it’s always nice to get a quick recap just to Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Trubion Collaboration with Facet Biotech

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corporation (Nasdaq: FACT) recently announced an agreement for the joint development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic. The collaboration agreement includes TRU-016 in all indications and all other CD37-directed protein therapeutics.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Complete Genomics Sequences 14 Human Genomes

Complete Genomics Inc. announced that 14 human genomes now have been sequenced, analyzed and delivered to customers since March 2009. The company’s human genome sequencing technology helps to further research for cancer, metabolic and neurological diseases. Customers include academic research institutions and biopharmaceutical companies that are conducting disease studies to investigate conditions as diverse as cancer (breast, lung, colorectal and melanoma), HIV and schizophrenia. Complete Genomics Inc. will be presenting at the 8th Annual BIO Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,